RQ-00317076 (AAT-076) / RaQualia - LARVOL DELTA

Drugs in Development to Manage Acute Pain. (PubMed, Drugs) - "These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain."

Journal • Review • Pain

Discovery and Development of a Centrally Active, Structurally Unique COX-2 Inhibitor (IASP 2024) - "AAT-076 demonstrated analgesic activity with an ED50 of 4.0 mg/kg v. 35 mg/kg for celecoxib in the carrageenan-induced hyperalgesia model. AAT-076 is a centrally active COX-2 inhibitor under development and has demonstrated potent efficacy in acute, chronic, and neuropathic pain models. AAT-076 is clinically validated, i.e., superior efficacy v. ibuprofen in terms of onset, potency, and duration of action, with a substantial safety database in clinical studies with ~800 subjects. AAT-076, with unique pharmacological properties, has the potential to offer patients an effective analgesic medication for acute and chronic pain conditions, and in so doing could help end the prescription opioid crisis."

Immunology • Inflammation • Neuralgia • Pain • Rheumatology

"#Korean Intellectual Property Office Grants #AskAt a Patent for the #AAT076 Production Process https://t.co/GWiIZVwc7p" (@1stOncology)

"#EuropeanPatentOffice Approves Formulation Patent for #AskAts #COX2Inhibitor (#AAT076) https://t.co/pw36bGrHuY" (@1stOncology)